Journal of affective disordersAdultFemaleHumansMaleMiddle Aged
Antidepressant efficacy and safety of scopolamine in individuals with bipolar disorder (SCOPE-BD): A randomized double-blind placebo-controlled trial.
Cerena Miravalles, Ruán Kane, Alison T Rossier, Jacqueline Quirke, David Alberto Aguilar Macías, Alberto Alvarez-Iglesias, Kelechi Chukwudi, Colm McDonald, Dara M Cannon, Brian Hallahan
Published: 202610.1016/j.jad.2025.120888
Abstract
BACKGROUND: Current treatments for depressive episodes in bipolar disorder are often limited by partial efficacy or delayed therapeutic response. Intravenous scopolamine, a pan-muscarinic antagonist, has shown rapid antidepressant effects in some stu…
Preview only. Read the full abstract at the source